健脾中药复方胃肠安对人胃癌裸小鼠原位移植瘤生长和转移的影响

Growth-inhibiting and anti-metastasis effects of Weichang'an Decoction on orthotopic transplant nude mouse model of human gastric cancer

目的:观察以健脾为基础的中药复方胃肠安对人胃癌裸小鼠原位移植瘤生长和转移的抑制作用。方法:采用人胃癌细胞SGC-7901,裸小鼠66只,其中41只制作原位移植瘤模型,另25只制作皮下移植瘤模型。两种模型的裸小鼠分别随机分为3组:胃肠安组,5-FU组和生理盐水对照组。胃肠安组予以含生药0.12g/ml的胃肠安煎剂0.5ml灌胃,1次/d;5-FU组以5-FU50mg/kg行腹腔化疗,1次/周;生理盐水对照组予以生理盐水0.5ml/d灌胃。原位移植瘤裸小鼠于造模后第64天处死;皮下移植瘤裸小鼠于造模后第41天处死。观察各组的抑瘤率,原位移植瘤各组肿瘤的转移情况,皮下移植瘤各组增殖细胞核抗原(pro-liferatingcellnuclearantigen,PCNA)和细胞凋亡情况。结果:原位移植瘤模型中,胃肠安组和5-FU组抑瘤率分别为40.82%和37.92%;皮下移植瘤模型中两组的抑瘤率则分别为48.70%和60.10%。原位移植瘤模型中,胃肠安组和5-FU组裸小鼠胃周淋巴结转移、肝转移、肝门淋巴结转移、横膈转移和腹膜转移比生理盐水对照组明显减少,3组的总转移率分别为30.77%、28.57%和71.43%(P<0.()5)。皮下移植瘤模型中,胃肠安组和5-FU组的PCNA总阳性率低于生理盐水对照组,细胞凋亡指数高于生理盐水对照组,差异有统计学意义(P<0.05或P<0.01)。胃肠安组和5-FU组瘤重、总转移率和PCNA总阳性率比较,差异无统计学意义,但胃肠安组细胞凋亡指数明显高于5-FU组(P<0.05)。结论:健脾中药复方胃肠安具有抑制人胃癌裸小鼠原位移植瘤生长和转移的作用。胃肠安对胃癌细胞的体内抑制作用可能通过抑制增殖、诱导肿瘤细胞凋亡而实现,对其抑制转移的机制尚需作进一步的研究。

Objective： To evaluate the growth-inhibiting and anti-metastasfs effects of Weicnangan uecoction （WOAD） on orthotopic transplant nude mouse model of human gastric cancer. Methods： Forty-one nude mice were implanted with SGC-7901 cells at orthotopic site, whereas 25 were implanted with SGO-7901 cells subcutaneously. Then the nude mice in each transplantation model were divided into the same three groups which were WOAD-treated group with WOAD 0.5 ml/d taken orally, 5-FU-treated group with 5-FU 50 mg/kg intraperitoneally injected weekly and untreated control group with physiological saline 0.5 ml/d taken orally. The growth-inhibiting rates of transplant tumors were detected and the metastatic lesions were examined in the orthotopic transplant mouse model while PCNA-positive rate and apoptotic index （Al） were observed in the subcutaneous transplant mouse model. Results： The growth-inhibiting rates in the WOAD-treated and 5- FU-treated groups of orthotopic transplant mouse model were 40.82% and 37.92% respectively whereas those of subcutaneous transplant mouse model were 48.70% and 60.10%. The incidence rates of metastasis in perigastric lymph notes, lymph nodes in the porta hepatis, liver, diaphragm and peritoneum in the WOAD- treated and 5-FU-treated groups were lower than those in the untreated control group, and the total metastasis rates in the WOAD-treated, 5-FU-treated and the untreated control groups were 30.77%, 28.57% and 71.43% respectively with significant differences （P〈0.05）. The total PONA-positive rates in the WOAD- treated and 5-FU-treated groups were obviously lower than that in the untreated control group （ P〈0.05 or P〈0.01 ） while the AI was higher than that in the untreated control group （P〈0.01）. The growth-inhibiting rate, total PONA-positive rate and total metastasis rate in the WOAD-treated group had no significant differences as compared with those in the 5-FU-treated group, but the AI in the WOAD-treated group was significantly higher than that in the 5-FU-treated group （P〈0.05）. Conclusion： WOAD has the inhibiting effects on tumor growth and metastasis of gastric cancer which is orthotopic implanted onto nude mice. This effect may be obtained by proliferation suppression and apoptosis induction in cancer.